RECURSION PHARMACEUTICALS, INC. Capital Expenditures
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Capital Expenditures of $302.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $44.00K, a 98.60% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $258.00K, a 85.92% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.24M, a 4.16% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $243.00K, a 94.67% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $6.47M, a 52.76% decline from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $13.70M, a 14.55% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $11.96M, a 67.74% decline from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $37.06M, a 6.88% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $302.00K 10-Q · filed 2026-08-05 | $1.55M derived: sum of 3 quarters · filed 2026-08-05 | $1.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $258.00K 10-Q · filed 2026-05-06 | $1.50M derived: sum of 2 quarters · filed 2026-05-06 | $1.75M derived: sum of 3 quarters · filed 2026-05-06 | $4.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.49M derived: sum of 2 quarters · filed 2026-02-25 | $4.64M derived: sum of 3 quarters · filed 2026-08-05 | $6.47M 10-K · filed 2026-02-25 |
| 2025-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.39M derived: sum of 2 quarters · filed 2026-08-05 | $5.22M 10-Q · filed 2025-11-05 | $6.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.98M 10-Q · filed 2026-08-05 | $6.28M derived: sum of 3 quarters · filed 2026-08-05 | $10.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-06 | $3.13M derived: sum of 2 quarters · filed 2026-05-06 | $7.69M derived: sum of 3 quarters · filed 2026-05-06 | $8.87M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.86M derived: sum of 2 quarters · filed 2026-02-25 | $7.04M derived: sum of 3 quarters · filed 2026-02-25 | $13.70M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.74M derived: sum of 2 quarters · filed 2025-11-05 | $12.40M 10-Q · filed 2025-11-05 | $14.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.83M 10-Q · filed 2025-08-05 | $9.90M derived: sum of 3 quarters · filed 2026-02-25 | $10.65M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $6.65M 10-Q · filed 2025-05-05 | $8.72M derived: sum of 2 quarters · filed 2026-02-25 | $9.46M derived: sum of 3 quarters · filed 2026-02-25 | $13.43M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.81M derived: sum of 2 quarters · filed 2026-02-25 | $6.78M derived: sum of 3 quarters · filed 2026-02-25 | $11.96M 10-K · filed 2026-02-25 |
| 2023-09-30 | $745.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.71M derived: sum of 2 quarters · filed 2024-11-06 | $9.89M 10-Q · filed 2024-11-06 | $17.87M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.14M 10-Q · filed 2024-08-08 | $17.12M derived: sum of 3 quarters · filed 2025-02-28 | $25.39M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $5.17M 10-Q · filed 2024-05-09 | $13.15M derived: sum of 2 quarters · filed 2025-02-28 | $21.42M derived: sum of 3 quarters · filed 2025-02-28 | $37.89M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $16.24M derived: sum of 2 quarters · filed 2025-02-28 | $32.72M derived: sum of 3 quarters · filed 2025-02-28 | $37.06M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $24.74M derived: sum of 2 quarters · filed 2023-11-09 | $29.08M 10-Q · filed 2023-11-09 | $33.54M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $16.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $20.82M 10-Q · filed 2023-08-08 | $25.28M derived: sum of 3 quarters · filed 2024-02-29 | $34.99M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $4.34M 10-Q · filed 2023-05-08 | $8.81M derived: sum of 2 quarters · filed 2024-02-29 | $18.51M derived: sum of 3 quarters · filed 2024-02-29 | $24.72M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $14.17M derived: sum of 2 quarters · filed 2024-02-29 | $20.38M derived: sum of 3 quarters · filed 2024-02-29 | $39.80M 10-K · filed 2024-02-29 |
| 2021-09-30 | $9.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $15.92M derived: sum of 2 quarters · filed 2022-11-08 | $35.33M 10-Q · filed 2022-11-08 | $39.02M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $6.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $25.63M 10-Q · filed 2022-08-09 | $29.32M derived: sum of 3 quarters · filed 2023-02-27 | $30.14M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $19.42M 10-Q · filed 2022-05-10 | $23.10M derived: sum of 2 quarters · filed 2023-02-27 | $23.93M derived: sum of 3 quarters · filed 2023-02-27 | $24.56M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $4.51M derived: sum of 2 quarters · filed 2023-02-27 | $5.15M derived: sum of 3 quarters · filed 2023-02-27 | $5.83M 10-K · filed 2023-02-27 |
| 2020-09-30 | $826.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.46M derived: sum of 2 quarters · filed 2021-11-10 | $2.14M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $634.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.32M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $684.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $3.91M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |